Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

Kelley V. FoyilWashington University School of Medicine, St. Louis, MO, USA

Dana A. KennedySeattle Genetics, Inc., Bothell, WA, USA

Laurie E. GroveSeattle Genetics, Inc., Bothell, WA, USA

Nancy L. BartlettWashington University School of Medicine, St. Louis, MO, USA

Amanda F. CashenWashington University School of Medicine, St. Louis, MO, USACorrespondence[email protected]

References

Younes A, Bartlett NL, Leonard JP, . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
PubMed Web of Science ®Google Scholar
Shustov AR, Advani R, Brice P, . Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2010;116(Suppl. 1): Abstract 961.
Google Scholar
Bartlett N, Grove LE, Kennedy DA, . Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series. J Clin Oncol 2010; 28(15 Suppl.): Abstract 8062.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date